NAD+ IV Therapy Side Effects: Risks, Warning Signs, and Safety

If you are researching NAD+ IV therapy side effects before booking, you deserve a more useful answer than "it is safe" or "just slow the infusion." Some discomfort reported during NAD+ drips may be sensitive to infusion rate. Other symptoms can point to an IV complication, an allergic reaction, contamination, or a separate medical problem.

This guide explains what has been reported, what the small human studies can and cannot tell us, when to stop, and what to ask a provider before treatment. It covers direct NAD+ IVs first, then briefly compares NAD injections and oral NAD+ precursors because evidence from one route should not be treated as proof for another.

In this guide

1. NAD+ side effects at a glance
2. What can happen during an NAD+ IV?
3. Why infusion rate matters
4. Warning signs and when to get help
5. What is known about long-term risks?
6. Who needs additional medical review?
7. IV vs injection vs oral supplements
8. FDA and sterile compounding concerns
9. Frequently asked questions

NAD+ IV therapy side effects at a glance

NAD+, or nicotinamide adenine dinucleotide, is a coenzyme involved in cellular energy metabolism and many other biological processes. That normal role in the body does not automatically make a concentrated intravenous product risk-free. Dose, infusion rate, other ingredients, sterile preparation, medical history, and the IV procedure itself can all affect the experience.

Reported symptom or risk	When it may occur	What to do
Nausea, abdominal cramping, diarrhea, or vomiting	These gastrointestinal symptoms have been reported during direct NAD+ infusions, including in a very small 2026 pilot study.	Tell the provider immediately. The infusion should be reassessed; repeated vomiting or worsening symptoms should not be pushed through.
Flushing, warmth, sweating, headache, or lightheadedness	These symptoms are described in clinical and commercial use, but reliable population-level frequency data are not available.	Report the symptom so the provider can check the infusion, vital signs, and possible causes.
Faster heart rate, palpitations, throat discomfort, congestion, or chest pressure	All were reported during infusion by participants in one six-person NAD+ group. That study is too small to estimate how often they occur.	Tell the provider at once. Chest symptoms, breathing trouble, fainting, or rapid worsening need urgent evaluation.
Pain, bruising, bleeding, swelling, or irritation at the IV site	These are risks of peripheral IV placement and can occur with any infusion.	Report burning, swelling, leaking, or increasing pain during the visit. Afterward, contact a clinician for spreading redness, warmth, drainage, red streaking, fever, or worsening pain.
Allergic reaction, infection, contamination, or fluid-related complication	These are less predictable and are not the same as ordinary infusion discomfort.	Stop and seek medical assessment. Call 911 for trouble breathing, facial or throat swelling, fainting, confusion, seizure, or other severe symptoms.

What side effects can happen during an NAD+ IV?

Direct human evidence is sparse. A 2026 retrospective pilot compared commercially administered 500 mg NAD+ IV with intravenous nicotinamide riboside. Only six adults received NAD+, each on four consecutive days. All six reported moderate to severe abdominal cramping, diarrhea, nausea, vomiting, increased heart rate, throat pain, congestion, and chest pressure during infusion. The symptoms stopped when the infusion ended, and discomfort led participants to reduce the infusion rate.

Those findings are important, but they are not a side-effect percentage for the general public. The study was small, retrospective, had no placebo group, used one 500 mg commercial protocol, and was designed and conducted by a commercial wellness company that employed the researchers. It provides a useful signal about tolerability, not a final answer about safety or how every dose will feel.

An earlier 2019 pilot followed eight participants during a six-hour NAD+ infusion and focused mainly on blood and urine metabolites. It did not provide a robust side-effect comparison or establish clinical effectiveness. Together, these studies show why confident claims about how common, rare, or harmless NAD drip side effects are should be treated cautiously.

Nausea and abdominal cramping

Gastrointestinal discomfort is one of the clearest recurring themes in the limited direct IV literature. Tell the provider at the first sign of nausea, cramping, diarrhea, or vomiting. A provider may pause or adjust the treatment while checking your symptoms and vital signs. Severe pain, repeated vomiting, blood in vomit or stool, fainting, or symptoms that continue or worsen after the infusion need additional medical care.

Headache, flushing, warmth, or lightheadedness

People and clinics report these symptoms, but published NAD+ IV studies do not yet provide dependable rates or a single proven mechanism for each one. Do not assume a headache or lightheaded feeling is automatically caused by NAD+. Hydration status, anxiety, blood pressure, other ingredients, medications, illness, and the IV procedure may also matter.

Increased heart rate, throat discomfort, and chest pressure

These symptoms appeared in the small 2026 NAD+ group and deserve prompt attention. Tell the provider immediately about a racing or irregular heartbeat, chest pressure, throat tightness, wheezing, or trouble breathing. A provider needs to distinguish transient discomfort from an allergic reaction, cardiovascular problem, or another urgent condition. Chest pain or pressure with shortness of breath, fainting, sweating, confusion, or pain spreading to the arm, jaw, back, or neck warrants emergency care.

Why NAD+ infusion rate matters, but is not the whole safety story

NAD+ drips are often administered more slowly when a person develops discomfort. In the 2026 pilot, participants controlled the rate based on tolerance, and symptoms led to longer infusion times. The authors also noted that slow, prolonged infusions are an anecdotal strategy and that formal studies defining the safest or best rate are lacking.

That distinction matters: slowing or pausing may improve some infusion-related symptoms, but it is not a substitute for assessment. A licensed provider should decide what happens next after checking the symptom, vital signs, IV site, ingredients, dose, and medical history. No one should be encouraged to endure chest symptoms, repeated vomiting, breathing problems, or severe shaking just to finish a bag.

Infusion time also varies by dose, protocol, tolerance, and provider direction. Review the more detailed NAD+ dose guide and the current IV menu and pricing, but do not choose a higher dose simply because it sounds more complete.

NAD+ warning signs: when should you stop or get help?

During an infusion, report every new symptom to the provider. Do not wait for it to become severe. The provider may need to stop or pause the infusion, check vital signs and the IV site, review all ingredients, or recommend a higher level of care.

• Call 911: chest pain or severe pressure, trouble breathing, facial or throat swelling, fainting, severe confusion, seizure, signs of stroke, or another rapidly worsening emergency.
• Get prompt medical advice: severe or persistent vomiting, significant abdominal pain, a sustained racing or irregular heartbeat, severe headache, marked weakness, or symptoms that do not improve after the infusion stops.
• Watch the IV site: increasing pain, swelling, coolness, burning, or leaking during treatment may mean the IV is not functioning properly.
• After the visit: spreading redness, warmth, pus or drainage, red streaking, fever, or worsening tenderness can signal infection and should be assessed.

Are there long-term side effects of NAD+ IV therapy?

The honest answer is that long-term safety is not well established. It is inaccurate to say that long-lasting side effects do not occur simply because the literature has not identified them. Absence of evidence is not evidence of absence, especially when the direct IV studies are small and follow-up is short.

The 2026 pilot followed laboratory and wearable measures for 30 days after four infusions, but only six people received NAD+. The authors called for longer and properly powered randomized trials. A 2019 study included eight NAD+ recipients and primarily examined metabolism during and shortly after a six-hour infusion. Neither study can rule out uncommon reactions, risks in people with different health conditions, or effects from repeated long-term use.

A 2023 systematic review evaluated varied NAD-related interventions, conditions, doses, and routes. That broader evidence should not be read as proof that direct NAD+ IV therapy has an established long-term safety profile. Oral nicotinamide riboside, oral nicotinamide mononucleotide, injections, and intravenous NAD+ are different products and routes.

Who needs additional medical review before NAD+ therapy?

There is no reliable one-size-fits-all list because direct IV NAD+ research in many patient groups is limited. A provider should review the reason for treatment, health history, medications, allergies, prior infusion reactions, current symptoms, and the planned ingredients before deciding whether an elective infusion is appropriate.

Make sure the provider knows if you:

• are pregnant, trying to become pregnant, or breastfeeding;
• have kidney, liver, heart, or significant blood-pressure problems;
• have a history of severe allergy, fainting with needles, or a prior IV reaction;
• take prescription medicines, over-the-counter drugs, or supplements;
• have an active infection, fever, vomiting, dehydration, chest symptoms, or another acute illness;
• are under treatment for cancer, a neurological condition, addiction, or another serious disease.

This list is not exhaustive. NAD+ IV therapy should not be presented as a treatment for cancer, Alzheimer's disease, Parkinson's disease, substance-use disorder, chronic fatigue syndrome, or another medical condition without adequate evidence and involvement from the clinician managing that condition.

NAD+ IV vs NAD injections vs oral supplements

Search results often group every form of "NAD therapy" together. That can be misleading because the ingredients, doses, absorption, side effects, and evidence differ.

Route	What it usually means	Important safety distinction
Direct NAD+ IV	NAD+ is delivered through a peripheral IV, often diluted in fluid and infused over time.	Reported infusion symptoms include gastrointestinal discomfort, increased heart rate, throat discomfort, and chest pressure. IV placement and sterile-product risks also apply.
NAD injection	A compounded product may be given by another route, such as intramuscular or subcutaneous injection, depending on the prescription and formulation.	NAD injection side effects and dosing cannot be assumed from IV studies. Injection-site pain, bruising, infection, allergy, formulation, and self-administration risks must be considered. Do not self-inject without appropriate prescribing and training.
Oral NAD+ precursors	Products commonly contain precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), not an IV dose of NAD+.	Oral studies do not prove IV safety or effectiveness. Supplement quality, dose, interactions, and product-specific evidence still matter.
Nasal, sublingual, or topical products	Commercial products may use different compounds and delivery claims.	Marketing claims about absorption and benefits should not be treated as established clinical evidence. Ask exactly what the product contains and what human data support that route.

Intravenous delivery bypasses the digestive tract, but that fact alone does not prove better health outcomes. The 2019 metabolism study found that directly infused NAD+ was rapidly removed from plasma during the first two hours and produced a changing metabolite pattern. It did not establish that an IV is clinically superior to an oral precursor.

FDA guidance, compounded NAD+, and sterile-product quality

NAD+ IV therapy is not an FDA-approved treatment. Many injectable NAD+ products are compounded drugs. FDA explains that compounded drugs are not reviewed before marketing for safety, effectiveness, or quality in the same way as FDA-approved drugs.

FDA has specifically warned compounders about using food-grade NAD+ ingredients to prepare sterile intravenous products. The agency said food-grade ingredients are not suitable for sterile compounding without appropriate processing because of microbial and endotoxin contamination risk. FDA also reported adverse events after NAD+ injectable products, including severe chills, shaking, vomiting, and fatigue, with some patients requiring medical treatment; the reported pattern was consistent with excessive endotoxins.

That warning does not mean every compounded NAD+ product is contaminated. It does mean sourcing and sterile preparation are meaningful safety questions, not fine print. Before treatment, consider asking:

• What exactly is in the infusion, including additives and fluid volume?
• Is the NAD+ product compounded, and what pharmacy prepared it?
• Was the ingredient intended and processed for sterile drug compounding?
• How are lot numbers, storage, beyond-use dates, and adverse reactions documented?
• Who reviews medical eligibility and who remains available during the infusion?
• What is the plan if symptoms occur or emergency care is needed?

How AZ IV Medics approaches NAD+ appointments

AZ IV Medics offers provider-reviewed NAD+ IV therapy in Arizona through mobile appointments and at the Scottsdale clinic, subject to medical eligibility and service availability. Before an infusion begins, the licensed provider reviews relevant health history, medications, allergies, current symptoms, and the requested service. The treatment plan and pace can be reassessed based on that review and how the patient responds.

The current menu lists several NAD+ dose options. A larger dose is not automatically the better starting point, and no dose guarantees a specific wellness result. Compare the 250 mg, 500 mg, and 1,000 mg NAD+ options, review current pricing, and ask the provider what fits your goals and history.

For broader context, read Is Mobile IV Therapy Safe? and check the Arizona mobile IV service areas. These resources explain provider credentials, general IV risks, and where mobile appointments may be available.

Frequently asked questions about NAD+ side effects

What are the most common NAD+ IV therapy side effects?

Reported symptoms include nausea, abdominal cramping, diarrhea, vomiting, headache, flushing or warmth, lightheadedness, increased heart rate, throat discomfort, congestion, and chest pressure. Reliable population-level rates are not available because direct human IV studies are small. Tell the provider about any symptom immediately.

Can NAD+ IV therapy cause chest pressure or a racing heart?

Yes, chest pressure and increased heart rate were reported during infusion in a small 2026 NAD+ pilot. These symptoms should be reported immediately and assessed, not automatically dismissed as a normal reaction. Call 911 for severe chest pain or pressure, trouble breathing, fainting, confusion, or rapidly worsening symptoms.

How long do NAD drip side effects last?

In the six-person NAD+ group from the 2026 pilot, the reported infusion symptoms stopped when infusion ended. That does not guarantee the same timeline for everyone or every cause. Persistent, severe, or worsening symptoms need medical advice, and emergency symptoms require 911.

Does slowing the NAD+ infusion reduce side effects?

Some infusion-related discomfort may improve when the rate is reduced or the infusion is paused. However, formal studies defining an optimal rate are lacking, and a slower rate cannot make every reaction safe. The provider should reassess symptoms before deciding whether to continue.

Are there long-term side effects of NAD+ IV therapy?

Long-term safety is not well established. Available direct IV studies are small and short. They cannot rule out uncommon reactions, effects in people with different health conditions, or risks from repeated long-term use.

Are NAD injection side effects the same as NAD+ IV side effects?

Not necessarily. The formulation, dose, route, absorption, and procedure differ. Injection-site pain, bruising, infection, allergic reaction, and product-quality risks may apply, while IV-specific rate and catheter risks are different. Evidence from one route should not be treated as proof for another.

Is NAD+ IV therapy FDA approved?

No. NAD+ IV therapy is not an FDA-approved treatment, and compounded NAD+ drugs are not reviewed by FDA before marketing for safety, effectiveness, or quality. FDA has also issued a specific alert about unsuitable food-grade NAD+ ingredients being used in sterile compounding.

Sources and medical references

• FDA: ingredients suitable for sterile compounding and NAD+ adverse-event reports
• FDA: consumer and healthcare professional information about compounded drugs
• Frontiers in Aging: retrospective NAD+ vs NR IV tolerability pilot
• PubMed: 2019 pilot of plasma and urine metabolites during NAD+ infusion
• PubMed: 2023 systematic review of NAD interventions
• ClinicalTrials.gov: current studies involving intravenous NAD